Att rney Docket No: 20200/2092 (Serial No.: 09/889,802)

Inventor: Kreutzer, et al. Filed: September 17, 2001 Third Preliminary Amendment

Page 4

- 236. (New ) The mammalian cell of claim 232, wherein the RNA transcript is a primary or a processed RNA
- 237. (New) The mammalian cell of claim 232, wherein the dsRNA comprises a linker between the two RNA strands.
- 238. (New) The mammalian cell of claim 232, wherein the linker is a polyethylene glycol linker.

## **REMARKS**

Applicants submit that no new fees are believed to be required for newly added claims 221-238, but hereby authorize the Commissioner to charge any additional claim fees to Deposit Account No. 16-0085, Reference No. 20200/2092.

Applicants respectfully request entry of the above amendments.

Date: February 5, 2003

Respectfully submitted,

Name: Barbara A/Gyure Registration No.: 34,614 Palmer & Dodge LLP 111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100



Attorney Docket N: 20200/2092 (Serial No.:09/889,802)

Inventor: Kreutzer, et al. Filed: September 17, 2001 Third Preliminary Amendment

Page i

## **MARKED-UP VERSION OF AMENDMENTS:**

## Specification Amendments Under 37 C.F.R. § 1.121(b)(1)(iii)

Please replace the title of the application with the title below, which is marked up by way of bracketing and underlining to show the changes relative to the previous version of the title:

## <u>COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A DEFINED</u> <u>GENE</u>

[METHOD AND MEDICAMENT FOR INHIBITING THE EXPRESSION OF A DEFINED GENE]